Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity

Mutagenesis

Volumn 18, Issue 4, 2003, Pages 345-353

  Lynch, Anthony ^a   Harvey, James ^a   Aylott, Michael ^a   Nicholas, Emma ^a   Burman, Mark ^a   Siddiqui, Ayesha ^a   Walker, Sarah ^a   Rees, Robert ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; BLEOMYCIN; CIPROFLOXACIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ELLIPTICINE; ETOPOSIDE; GENISTEIN; MITOXANTRONE;

ANIMAL CELL; ARTICLE; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CLEAVAGE; DNA STRAND BREAKAGE; DRUG POTENCY; GENOTOXICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPHOMA CELL; MICRONUCLEUS TEST; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL MODEL; TIME;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CIPROFLOXACIN; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; GENISTEIN; LYMPHOMA; MICE; MUTAGENS;

ANIMALIA;

EID: 0037818408     PISSN: 02678357     EISSN: None     Source Type: Journal    
DOI: 10.1093/mutage/geg003     Document Type: Article

References (41)

1. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M. and Fukami, Y. (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262, 5592-5595.
2. Albertini, S., Chatelat, A.-A., Miller, B., Muster, W., Pujadas, E., Strobel, R. and Gocke, E. (1995) Genotoxicity of 17 gyrase and 4 mammalian topoisomerases II-poisons in prokaryotic and eukaryotic test systems. Mutagenesis, 10, 343-351.
3. Applegate, M.L., Moore, M.M., Broder, C.B., Burrell, A., Juhn, G., Kasweck, K.L., Lin, P.F., Wadhams, A. and Hozier, J.C. (1990) Molecular dissection of mutations at the heterozygous thymidine kinase locus in mouse lymphoma cells. Proc. Natl Acad. Sci. USA, 87, 51-55.
4. Ashby, J., Tinwell, H., Glover, P., Poorman-Allen, P., Krehl, R., Callander, R.D. and Clive, D. (1994) Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella responses. Environ. Mol. Mutat., 35, 12-31.
5. Bartholomew, R.M. and Ryan, D.S. (1980) Lack of mutagenicity of some phytoestrogens in the Salmonella/mammalian microsome assay. Mutat. Res., 78, 317-321.
6. Baguley, B.C. and Ferguson, L.R. (1998) Mutagenic properties of topoisomerase-targeted drugs. Biochim. Biophys. Acta, 1400, 213-222.
7. Berger, J.M. (1998) Structure of DNA topoisomerases. Biochim. Biophys. Acta, 1400, 3-18.
8. Burden, D.A. and Osheroff, N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1400, 139-154.
9. Capranico, G., De Isabella, P., Penco, S., Tinelli, S. and Zunino, F. (1989) Role of DNA breakage in cytotoxicity of doxorubicin, 9-deoxydoxorubicin and 4-demethyl-6-deoxydoxorubicin in murine leukaemia P388 cells. Cancer Res., 49, 2022-2027.
10. Countryman, P. and Heddle, J. (1976) The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat. Res., 41, 321-332.
11. Cummings, J., Anderson, L., Willmott, N. and Smyth, J.F. (1991) The molecular pharmacology of doxorubicin in vivo. Eur. J. Cancer, 27, 532-535.
12. Davis, J.N., Singh, B., Bhuiyan, M. and Sarkar, F.H. (1998) Genistein-induced upregulation of p21WAF1, downregulation of cyclin B and induction of apoptosis in prostate cancer cells. Nutr. Cancer, 32, 123-131.
13. Doroshow, J.H. (1996) Anthracyclines and anthracenediones. In Chabner, B.A. and Longo, D.L. (eds), Cancer Chemotherapy and Biotherapy: Principles and Practise, 2nd Edn. Lippincott-Raven, Philadelphia, PA, pp. 409-434.
14. Draper, N.R. and Smith, H. (1981) Applied Regression Analysis. Wiley, New York, NY.
15. Edler, L. and Kopp-Schneider, A. (1998) Statistical models for low dose exposure. Mutat. Res., 402, 227-236.
16. Elhajouji, A., Van Hummelen, P. and Kirsch-Volders, M. (1995) Indications for a threshold of chemically induced aneuploidy in-vitro in human lymphocytes. Environ. Mol. Mutat., 26, 292-304.
17. Elhajouji, A., Tibaldi, F. and Kirsch-Volders, M. (1997) Indications for thresholds of chromosome non-disjunction versus chromosome lagging induced by spindle inhibitors in vivo in human lymphocytes. Mutagenesis, 12, 133-140.
18. Fortune, J.M. and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog. Nucleic Acid Res. Mal. Biol., 64, 221-523.
19. Gerwitz, D.A. (1999) A critical evaluation of the mechanisms of action proposed for the antitumour effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 57, 727-741.
20. Gootz, T.D. and Brightly, K.E. (1998) Chemistry and mechanism of action of the quinolone antibacterials. In Andriole, V.T. (ed.), The Quinolones, 2nd Edn. Academic Press, San Diego, CA, pp. 27-80.
21. Herbold, B.A., Brendler-Schwaab, S.Y. and Ahr, H.J. (2001) Ciprofloxacin: in vivo genotoxicity studies. Mutat. Res., 498, 193-205.
22. Hsiang, Y.H. and Liu, L.F. (1998) Evidence for the reversibility of cellular DNA lesions induced by mammalian topoisomerase II poisons. J. Biol. Chem. 264, 9713-9715.
23. Kim, H., Peterson, T.G. and Barnes, S. (1998) Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways. Am. J. Clin. Nutr., 68 (suppl. 6), 1418S-1425S.
24. Kirsch-Volders, M., Aardema, M. and Elhajouji, A. (2000) Concepts of threshold in mutagenesis and carcinogenesis. Mutat. Res., 464, 3-11.
25. Kulling, S.E. and Metzler, M. (1997) Induction of micronuclei, DNA strand breaks and HPRT mutations in cultured Chinese hamster V79 cells by the phytoestogen cumoestrol. Food Chem. Toxicol., 35, 605-613.
26. Lovell, D.P. (2000) Dose-response and thresholds-mediated mechanisms in mutagenesis: statistical models and study design. Mutat. Res., 464, 87-95.
27. Lutz, W. (1998) Dose-response relationship in chemical carcinogenesis; superposition of different mechanisms of action, resulting in linear nonlinear curves, practical thresholds, J-shapes. Mutat. Res., 405, 117-124.
28. Markovits, J., Linassier, C., Fosse, P., Couprie, J., Pierre, J., Jacquemin-Sablon, A., Saucier, J.M., Le Pecq, J.B. and Larsen, A.K. (1989) Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res., 49, 5111-5117.
29. Morris, S.M., Chen, J.J., Domon, O.E., McGarrity, L.J., Bishop, M.E., Manjanatha, M.G. and Casciano, D.A. (1998) Mutations and apoptosis in genistein-exposed human lymphoblastoid cells. Mutat. Res., 405, 41-56.
30. Müller, L. and Kasper, P. (2000) Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat. Res., 464, 19-34.
31. Record, I.R., Jannes, M., Dreosti, I.E. and King, R.A. (1995) Induction of micronucleus formation in mouse splenocytes by the soy isoflavone genistein in vitro but not in vivo. Food Chem. Toxicol., 33, 919-922.
32. Schneiderman, M.A., Decoufle, P. and Brown, C.C. (1979) Thresholds for environmental cancer: biologic and statistical considerations. Ann. N. Y. Acad. Sci., 329, 92-130.
33. 1 cell-cycle arrest in human prostate cancer cells. Mol. Carcinog., 29, 92-102.
34. Sofuni, T., Hayashi, M., Nohmi, T., Matsuoka, A., Yamada, M. and Kamata, E. (2000) Semi-quantitative evaluation of genotoxic activity of chemical substances and evidence for a biological threshold of genotoxic activity. Mutat. Res., 464, 97-104.
35. Takahashi, N., Shiahara, T., Kaneko, E., Itoh, T., Shiragiku, T., Awogi, T. and Shibuya, T. (1994) Genotoxicity studies of grepafloxacin. Japn. Pharmacol. Ther., 22, 4567-4577.
36. Takayama, S., Hirohashi, M., Kato, M. and Shimada, H. (1995) Toxicity of quinolone antimicrobial agents. J. Toxicol. Environ. Heath, 45, 1-45.
37. Tewey, K.M., Rowe, T.C., Yang, L., Halligan, B.D. and Liu, L.F. (1994) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 226, 466-468.
38. Willmore, E., Frank, A.J., Padget, K., Tilby, M.J. and Austin, C.A. (1998) Etoposide targets topoisomerase II alpha and II beta in leukemic cells: isoform-specific cleavable complexes visualised and quantified in-situ by a novel immunofluorescence technique. Mol. Pharmacol., 54, 78-85.
39. Willmore, E., Errington, F., Tilby, M.J. and Austin, C.A. (2002) Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells. Biochem. Pharmacol., 63, 1807-1815.
40. Yamashita, Y., Kawada, S. and Nakano, H. (1990) Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem. Pharmacol., 39, 737-744.
41. Zwelling, L.A., Michaels, S., Erickson, L.C., Ungerleider, M.N., Nichols, M. and Kohn, K. (1981) Protein-associated deoxyribonucleic acid intercalating agents 4′-(9-acridinylamino methanesulfon-m-anisidide and adriamycin. Biochemistry, 20, 6553-6563.